Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients

Rheumatology International

Volumn 32, Issue 3, 2012, Pages 743-748

  Mittal, Niti ^a   Sharma, Aman ^a   Jose, Vinu ^a   Mittal, Rakesh ^b   Wanchu, Ajay ^a   Bambery, Pradeep ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b Adesh University   (India)

Author keywords

Adverse drug reactions; Disease modifying anti rheumatic drugs; Rheumatoid arthritis; Withdrawal

Indexed keywords

AMITRIPTYLINE; CHLOROQUINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; ISOXAZOLE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CELL COUNT; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL IRRITATION; GENETIC DIFFERENCE; GENETIC VARIABILITY; HEADACHE; HUMAN; INDIAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; DRUG COMBINATION; DRUG TOXICITY; INDIA; MIDDLE AGED; TIME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HUMANS; HYDROXYCHLOROQUINE; INDIA; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFASALAZINE; TIME FACTORS;

EID: 84863302243     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1646-4     Document Type: Article

References (61)

1. Malaviya AN, Kapoor SK, Singh RR et al (1993) Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 13:131-134 (Pubitemid 24018727)
2. Bedi GS, Gupta N, Handa R et al (2005) Quality of life in Indian patients with rheumatoid arthritis. Qual Life Res 14:1953-1958 (Pubitemid 41279618)
3. Aggarwal A, Chandran S, Misra R (2006) Physical, psychosocial and economic impact of rheumatoid arthritis: a pilot study of patients seen at a tertiary care referral centre. Natl Med J India 19:187-191 (Pubitemid 44596405)
4. Gabriel SE, Crowson CS, Kremers HM et al (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48:54-58 (Pubitemid 36091647)
5. Chakravarty K, McDonald H, Pullar T et al (2008) BSR & BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 47:924-925
6. Nell VPK, Machold KP, Eberl G et al (2004) BeneWt of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43:906-914 (Pubitemid 38996967)
7. Luqmani R, Hennell S, Estrach C et al (2006) British society for rheumatology and british health professionals in rheumatology guideline for the management of rheumatoid arthritis (the Wrst two years). Rheumatology (Oxford) 45:1167-1169 (Pubitemid 44542111)
8. Choy EHS, Smith C, Dore CJ et al (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44:1414-1421 (Pubitemid 41631866)
9. Handa R (2004) Management of rheumatoid arthritis. Natl Med J India 17:143-151 (Pubitemid 38868220)
10. American College of Rheumatology Ad hoc Committee on Clinical Guidelines (1996) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39:713-722
11. American College of Rheumatology Ad hoc Committee on Clinical Guidelines (1996) Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 39:723-731
12. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 46:328-346
13. Joshi VR (2002) Indian guidelines for the management of rheumatoid arthritis. J Assoc Physicians India 50:1207-1218
14. Van der Heijden JW, Dijkmans BA, Scheper RJ et al (2007) Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside. Nat Clin Pract Rheumatol 3:26-34
15. Bingham S, Emery P (2000) Resistant rheumatoid arthritis clinics- a necessary development? Rheumatology (Oxford) 39:2-5 (Pubitemid 30095399)
16. GriYths B, Situnayake RD, Clark B et al (2000) Racial origin and its effect on disease expression and HLA-DRB1 types in patients with rheumatoid arthritis: a matched cross-sectional study. Rheumatology (Oxford) 39:857-864 (Pubitemid 30654757)
17. Bruce N, Cronstein MD (2006) Pharmacogenetics in the rheumatic diseases. Bull NYU Hosp Jt Dis 64:16-19
18. Taniguchi A, Urano W, Tanaka E et al (2007) Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis. Nippon Rinsho 65:371-379
19. Ranganathan P (2005) Pharmacogenetics of therapies in rheumatoid arthritis. Drugs Today (Barc) 41:799-814 (Pubitemid 43333356)
20. Tanaka E, Taniguchi A, Urano W et al (2004) Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol 18:233-247 (Pubitemid 38684478)
21. Taniguchi A, Urano W, Tanaka E et al (2002) Pharmacogenetics of disease modifying anti-rheumatic drugs. Nippon Rinsho 60:2339-2344
22. Maetzel A, Wong A, Strand V et al (2000) Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 39:975-981
23. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324 (Pubitemid 18091653)
24. Maddison P, Kiely P, Kirkham B et al (2005) LeXunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology 44:280-286 (Pubitemid 40361281)
25. Pavelka K, Forejtová K, Pavelková A et al (2002) Analysis of the reasons for DMARD therapy discontinuation in patients with rheumatoid arthritis in the Czech and Slovak Republics. Clin Rheumatol 21:220-226 (Pubitemid 34785011)
26. Nagashima M, Matsuoka T, Saitoh K et al (2006) Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol 24:260-267 (Pubitemid 44151144)
27. Hoekstra M, van Ede AE, Haagsma CJ et al (2003) Factors associated with toxicity, Wnal dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62:423-426 (Pubitemid 36469732)
28. van Ede E, Laan RFJM, Blom HJ et al (2002) Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 41:658-665 (Pubitemid 34618884)
29. van Ede AE, Laan RF, Rood MJ et al (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515-1524 (Pubitemid 32651731)
30. Joyce DA, Will RK, HoVman DM et al (1991) Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 50:913-914
31. Pawlik A, Czerny B, Dabrowska-Zamojcin E et al (2005) The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone. Pol Arch Med Wewn 114:843-847 (Pubitemid 43341685)
32. Wessels JA, Kooloos WM, De Jonge R et al (2006) Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 54:2830-2839 (Pubitemid 44497761)
33. Dervieux T, Furst D, Lein DO et al (2005) Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 64:1180-1185 (Pubitemid 41113353)
34. Van Ede AE, Laan RF, Blom HJ et al (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525-2530 (Pubitemid 33049330)
35. Hughes LB, Beasley TM, Patel H et al (2006) Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 65:1213-1218 (Pubitemid 44277399)
36. Weisman MH, Furst DE, Park GS et al (2006) Risk genotypes in folate-dependent enzymes and their association with methotrexate- related side effects in rheumatoid arthritis. Arthritis Rheum 54:607-612 (Pubitemid 43228638)
37. Krajinovic M, Moghrabi A (2004) Pharmacogenetics of methotrexate. Pharmacogenomics 5:819-834 (Pubitemid 39386751)
38. Ranganathan P, Eisen S, Yokoyama WM et al (2003) Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 62:4-9 (Pubitemid 36005787)
39. Kremer JM (2006) Methotrexate pharmacogenomics. Ann Rheum Dis 65:1213-1218
40. Suarez-Almazor ME, Belseck E, Shea BJ et al (2000) Sulfasalazine for treating rheumatoid arthritis (review). Cochrane Database Syst Rev 2:CD000958
41. Wadelius M, Stjernberg E, Wiholm BE et al (2000) Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics 10:35-41 (Pubitemid 30142811)
42. Tanaka E, Taniguchi A, Urano W et al (2002) Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 29:2492-2499 (Pubitemid 35416951)
43. Kitas GD, Farr M, Waterhouse L et al (1992) InXuence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 21:220-225
44. Bax DE, Greaves MS, Amos RS (1986) Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Br J Rheumatol 25:282-284 (Pubitemid 16037874)
45. Pullar T, Hunter JA, Capell HA (1985) EVect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis 44:831-837 (Pubitemid 16222237)
46. Kumagai S, Komada F, Kita T et al (2004) N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm Res 21:324-329 (Pubitemid 38221979)
47. Teshima D, Hino B, Makino K et al (2003) Sulphasalazineinduced leucopenia in a patient with renal dysfunction. J Clin Pharm Ther 28:239-242 (Pubitemid 36783101)
48. van der Heijden J, de Jong MC, Dijkmans BAC et al (2004) Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to nonrelated DMARDs. Ann Rheum Dis 63:131-137 (Pubitemid 38122130)
49. Mohanty D, Mukherjee MB, Colah RB (2004) Glucose-6-phosphate dehydrogenase deficiency in India. Indian J Pediatr 71:525-529 (Pubitemid 38917394)
50. Mavrikakis M, Papazoglou S, SWkakis PP et al (1996) Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 55:187-189 (Pubitemid 26076732)
51. Mavrikakis I, SWkakis PP, Mavrikakis E et al (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 110:1321-1326 (Pubitemid 36842465)
52. Osiri M, Shea B, Robinson V et al (2003) LeXunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 1:CD002047
53. Laivoranta-Nyman S, Mottonen T, Hannonen P et al (2006) Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis. Clin Exp Rheumatol 24:636-642 (Pubitemid 46138794)
54. O'Dell JR, Nepom BS, Haire C et al (1998) HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 57:209-213 (Pubitemid 28323261)
55. Kuuliala K, Orpana A, Leirisalo-Repo M et al (2006) Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis. Ann Rheum Dis 65:1241-1243 (Pubitemid 44277406)
56. Gotzsche PC, Johansen HK (2004) Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 3:CD000189
57. Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S (1996) Low-dose corticosteroids in rheumatoid arthritis. A metaanalysis of their moderate-term effectiveness. Arthritis Rheum 39:1818-1825 (Pubitemid 26378706)
58. Seideman P (1993) Additive effect of combined naproxen and paracetamol in rheumatoid arthritis. Br J Rheumatol 32:1077-1082 (Pubitemid 23363241)
59. Seideman P (1993) Paracetamol in rheumatoid arthritis. Agents Actions Suppl 44:7-12 (Pubitemid 23211950)
60. Frank RG, Kashani JH, Parker JC et al (1988) Antidepressant analgesia in rheumatoid arthritis. J Rheumatol 15:1632-1638 (Pubitemid 19027781)
61. Saarto T, WiVen PJ (2005) Antidepressants for neuropathic pain. Cochrane Database Syst Rev 3:CD005454